Inventor
CASTORENO ADAM
US22 patents
Patents
22 patentsUS11326166B1May 10, 2022
Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations72
US11149276B2Oct 19, 2021
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations72
US11926832B2Mar 12, 2024
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC4 citations71
US11959081B2Apr 16, 2024
Transthyretin (TTR) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations62
US12480125B2Nov 25, 2025
Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations61
US12397013B2Aug 26, 2025
Extrahepatic delivery
ALNYLAM PHARMACEUTICALS INC0 citations61
US12005074B2Jun 11, 2024
Extrahepatic delivery
ALNYLAM PHARMACEUTICALS INC0 citations61
US11649459B2May 16, 2023
Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases
ALNYLAM PHARMACEUTICALS INC0 citations61
US12522822B2Jan 13, 2026
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations60
US12018260B2Jun 25, 2024
Tunable Reversir™ compounds
ALNYLAM PHARMACEUTICALS INC0 citations60
US11162103B2Nov 2, 2021
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations60
US12565653B2Mar 3, 2026
ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations59
US12404508B2Sep 2, 2025
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations59
US11993774B2May 28, 2024
Huntingtin (HTT) iRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations59
US11965166B2Apr 23, 2024
Complement factor B (CFB) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations59
US11034957B2Jun 15, 2021
Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations59
US12365896B2Jul 22, 2025
Complement component C3 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations58
US12258565B2Mar 25, 2025
Complement component C3 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations58
US12049630B2Jul 30, 2024
Factor XII (F12) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC1 citations56
US12534731B2Jan 27, 2026
Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations55
US12516322B2Jan 6, 2026
Microtubule associated protein Tau (MAPT) iRNA agent compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations53
US12416006B2Sep 16, 2025
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations43